Digene Signs Deal with Quest for Routine HPV DNA Testing | GenomeWeb

NEW YORK, Jan. 27 (GenomeWeb News) - Quest Diagnostics has agreed to market Digene's DNA-based test for human papillomavirus (HPV), Digene said today.

Under the three-year agreement, Quest will offer physicians Digene's HPV test for routine cervical cancer screening in conjunction with the Pap test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.